A multicenter clinical study10 on the efficacy of the HER kinase inhibitor neratinib showed that the responses of patients were determined by both cancer types and mutations, which is consistent with the conclusion of a previous clinical study14 in which the BRAF inhibitor vemurafenib was tested on patients from different cancer types but harboring BRAF V600 mutation. This evidence concerns the gene BRAF and cancer.